gip/glp-1 receptor agonist drugs Science Behind GLP 1 GIP and Glucagon Agonists for Obesity Research | News & Announcements Schematic illustration of monoagonists, dual

Agents such as dulaglutide, liraglutide, semaglutide, and tirzepatide differ in pharmacology and dosing, directly influencing perioperative safety, particularly due to their effects on gastric motility and the high frequency of gastrointestinal (GI) adverse events that raise concerns about aspiration and postoperative morbidity in urgent or elective procedures

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials

Eli Lilly have a new, once-monthly GLP1/GIP agonist (Brenipatide) and they're running some fascinating trials with it Smoking cessation, bipolar disorder, schizophrenia, opioid use disorder, depression, alcohol use disorder, and asthma

Get the details at ADW Diabetes.

It can sound weak and idealistic but make no mistake: all 3 ingredients in our natural GLP-1 product have been rigorously studied in human clinical trials